Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis
Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis
This study evaluates the effect of sublimated mare milk supplement on patients with biliary
 cholangitis
Primary biliary cholangitis, formerly known as primary biliary cirrhosis, is a rare chronic
 disease that primarily affects women. Primary biliary cholangitis often progresses to the
 terminal stage of liver cirrhosis with its inherent complications. At this stage, the only
 way to save the patient's life is liver transplantation, and is accompanied by a number of
 painful symptoms (itching, mucous dryness, abdominal discomfort, fatigue), often restless
 legs syndrome, insomnia, depression and cognitive dysfunction.

 The goal of the treatment is to prevent the terminal stage of cirrhosis of the liver and to
 alleviate the accompanying symptoms. Conventional drug therapy is aimed at slowing the
 progression of the disease and includes both approved for the use of these medications
 (ursodeoxycholic acid) and used outside the approved indications (derivatives of fibric acid,
 budesonide).

 The role of this clinical trial is to increase the effectiveness of therapy for this disease.
 Against the background of the complexity of the treatment of primary biliary cholangitis,
 clinical medicine acquires a remedy in the form of a natural product - mare's milk,
 preventive, dietary, medicinal effects of which have been known for a long time. There are
 data from studies that have shown the efficacy and safety of using mare milk in patients with
 atopic dermatitis as well as with inflammatory bowel diseases. For the liver diseases, there
 are no reported studies.

 In this trial, there will be two parallel groups: Interventional (supplement with standard
 treatment first for 3 months) and Standard treatment group. Differences in clinical,
 laboratory, liver encephalopathy and asthenia will be evaluated between groups.
Inclusion Criteria:

 -  Patients with morphologically verified diagnosis of primary biliary cholangitis

 -  Aged 18 to 75 years

 -  Willingness to consent to participate in the study

 -  Consent to adhere to treatment

 Exclusion Criteria:

 -  Alcohol and/or drug dependence

 -  Presence of liver cirrhosis class C based on Child Pugh classification

 -  Allergic reaction to dairy products

 -  Presence of mental diseases, severe concomitant pathology

 -  Pregnancy and/or lactation

 -  Lactose intolerance

 -  Refusal to participate in the study